Data cannot be shared publicly because of sensitive patient information. Data are available from the Ethics Committee of the VU University Medical Center ([contact via metc\@vumc.nl](mailto:contact via metc@vumc.nl)) for researchers who meet the criteria for access to confidential data.

Introduction {#sec005}
============

Glycated haemoglobin (HbA~1c~) is widely adopted as diagnostic marker for type 2 diabetes and reflects average plasma glucose levels over the prior two to three months \[[@pone.0233769.ref001], [@pone.0233769.ref002]\]. The use of HbA~1c~ for diagnosis has several advantages over measurements of fasting plasma glucose (FPG) and 2h post-load plasma glucose (2hPG), which include lower intra-individual variation and more convenience in blood sampling conditions \[[@pone.0233769.ref003]\]. HbA~1c~ has also been shown to be a more accurate marker than measures of glucose for future risk of diabetes complications, such as micro vascular complications and cardiovascular disease (CVD), in individuals with type 2 diabetes \[[@pone.0233769.ref004]\]. In addition, higher HbA~1c~ is associated with higher risk for CVD and total mortality \[[@pone.0233769.ref005], [@pone.0233769.ref006]\]. This increased CVD and mortality risk with higher HbA~1c~ is already seen at levels in the normal range \[[@pone.0233769.ref005], [@pone.0233769.ref006]\].

Nonetheless, controversy exists regarding the use of HbA~1c~ as a diagnostic marker for type 2 diabetes in the general population, since several population-based studies have shown that correlations between glucose and HbA~1c~ are relatively poor \[[@pone.0233769.ref007]\]. Furthermore, several studies have suggested that HbA~1c~ levels are affected by other factors than glucose alone \[[@pone.0233769.ref008]--[@pone.0233769.ref010]\]. Multiple studies found that HbA~1c~ might not be a reliable reflection of glycemic state in individuals with iron or vitamin B12 deficiency, renal or liver failure, short erythrocyte lifespan, rheumatoid arthritis, alcoholism, and in individuals who use aspirin, vitamin -C, -E supplements or antiretrovirals \[[@pone.0233769.ref011], [@pone.0233769.ref012]\]. To better understand the effects of such conditions on HbA~1c~, a more comprehensive understanding of determinants of HbA~1c~ is needed.

A small number of studies revealed that, independent of glucose, non-Hispanic black race, smoking, several genetic risk factors and higher age and BMI are associated with a higher HbA~1c~ level, whereas higher alcohol consumption, haemoglobin mass and concentration are associated with a lower HbA~1c~ level \[[@pone.0233769.ref013]--[@pone.0233769.ref016]\]. Another previous study showed that in individuals without diabetes, 2hPG explains only one quarter to one third of the variance in HbA~1c~ \[[@pone.0233769.ref009]\]. Furthermore, researchers of the Lifeline Cohort Study recently found that a combination of clinical, lifestyle and genetic factors, in addition to FPG, explained 26.2% of the variance in HbA~1c~, with FPG contributing 10.9% \[[@pone.0233769.ref013]\]. Exploring determinants in addition to both FPG and 2hPG provides better insight into the added value of other determinants, since the combination of FPG and 2hPG is a better reflection of glycemic state and diurnal glucose \[[@pone.0233769.ref017]\].

A better understanding of the variance in HbA~1c~ is relevant for the interpretation of HbA~1c~ levels in the general population. The present study therefore aims to investigate the relative contribution of previously identified determinants to HbA~1c~, independent of FPG and 2hPG, in the general population.

Subjects, materials and methods {#sec006}
===============================

Study population {#sec007}
----------------

The current study was performed using baseline data from the Hoorn Study, a population based cohort study conducted among men and women from the general population residing in the city of Hoorn, the Netherlands \[[@pone.0233769.ref018]\]. For the first wave of the Hoorn Study a total of 3553 participants aged between 49 and 75 years were invited and 2540 agreed to participate in the study, of which 56 non-Caucasians were excluded. In the present study, we excluded 90 participants with known diabetes based on GP diagnosis and/or use of glucose-lowering medication at baseline and 15 participants with missing data on diabetes status. Furthermore, we excluded 69 participants without data on dietary intake variables and one participant with an extreme value for total energy (\<500 or \>5000 kcal/day), leaving 2309 participants for analysis. Baseline data were collected from October 1989 until February 1992.

The second wave was conducted July 2006 until November 2007 and a total of 6180 men and women aged 40--65 years were invited, of which 2807 agreed to participate in the study \[[@pone.0233769.ref018]\]. In the present study, we excluded 82 participants with known diabetes based on GP diagnosis and/or use of glucose-lowering medication at baseline and 54 participants with missing data on diabetes status. Furthermore, we excluded 43 participants without data on dietary intake variables and nine participants with extreme values for total energy (\<500 or \>5000 kcal/day), leaving 2619 participants for analysis. Informed consent was signed by all participants and both studies were approved by the Ethical Review Committee of the VU University medical center (VUmc).

Baseline measurements {#sec008}
---------------------

In the first wave, anthropometric measurements were taken at the first visit with participants being barefoot and wearing light clothes \[[@pone.0233769.ref018]\]. Data on dietary intake and alcohol consumption were obtained from a 75-item self-reported semi quantitative food frequency questionnaire (FFQ) \[[@pone.0233769.ref019]\]. Energy and nutrient intakes were estimated from FFQ through linkage with a computerized version of the Dutch Food Composition Table \[[@pone.0233769.ref020]\]. The FFQ was validated against a dietary history for total energy intake, all macronutrients, dietary fiber, alcohol, iron, vitamins B1, B6 and vitamin C. Pearson correlation coefficients were on average 0.71 (range: 0.65--0.78) for macronutrients, and 0.66 (range: 0.36--0.81) for vitamins and minerals \[[@pone.0233769.ref019]\]. Cigarette smoking status was self-reported.

In the second wave, the same methods as in the first wave were used for anthropometric measurements and cigarette smoking status \[[@pone.0233769.ref018]\]. Data on dietary intake and alcohol consumption were obtained from a 125-item self-reported quantitative FFQ. The Dutch Food Composition Table of 2006 was used to calculate energy and nutrient intake per day \[[@pone.0233769.ref021]\]. This FFQ was validated for total energy intake against actual energy intake needed to maintain stable body weights during 11 controlled dietary trials, with a Pearson correlation coefficient of 0.82 (95% CI, 0.80, 0.85) \[[@pone.0233769.ref022]\].

Laboratory assays {#sec009}
-----------------

In the first wave, an oral glucose tolerance test (OGTT) was performed after an overnight fast and blood samples were collected before and 2 hours after intake of the glucose load \[[@pone.0233769.ref018]\]. FPG and 2hPG levels were determined with the glucose dehydrogenase method (Merck, Darmstadt, Germany). HbA~1c~ was assessed with an ion exchange high performance liquid chromatography (Modular Diabetes Monitoring System, BioRad Lab, Veenendaal, The Netherlands: normal range 4.3‒6.1%). Alanine transaminase enzyme activity was measured in plasma as a marker of liver function \[[@pone.0233769.ref023]\]. This measurement was conducted according to the method of the International Federation of Clinical Chemistry from 1985 and expressed as IU/L. Serum creatinine was measured as indicator of renal function \[[@pone.0233769.ref024]\].

In the second wave, the same methods were used for the OGTT \[[@pone.0233769.ref018]\]. FPG and 2hPG levels were measured with the glucose oxidase method (Boehringer-Mannheim, Mannheim, Germany). HbA~1c~ was assessed using the Diabetes Control and Complications Trial (DCCT) standardized reverse-phase cation exchange chromatography (Menarini, Florence, Italy), for which the intra-assay coefficient of variation was 0.65% at a mean of 4.89%, and the interassay coefficient of variation was 1.55% at a mean of 5.52% \[[@pone.0233769.ref025]\]. In both studies, all analyses were performed at the clinical chemistry laboratory of the VUmc.

Statistical analysis {#sec010}
--------------------

Characteristics of the study populations are presented as mean ± SD for normally distributed continuous variables or median (25^th^-- 75^th^ percentile) for positively skewed distributions. Categorical variables are presented as proportions. Missing data (0.1% of all observations in the first wave and 0.2% in the second wave) were imputed using multiple imputation, creating five imputed datasets. The Multivariate Imputation by Chained Equations (MICE) algorithm was used with the predictive mean matching method \[[@pone.0233769.ref026]\]. Results of the analyses were pooled using Rubin's rules \[[@pone.0233769.ref027]\].

Correlations between FPG, 2hPG and HbA~1c~ were determined using Spearman correlations. Linear and quadratic associations of the determinants with HbA~1c~ were added in the linear regression model to test for non-linear associations. Determinants for which the quadratic term was significant (*P* \< 0.05) were divided into quartiles. Dietary intake variables were corrected for total energy intake by the residual method \[[@pone.0233769.ref028]\].

Using data from the first wave, a multivariate linear regression model with outcome HbA~1c~ was created including FPG and 2hPG as fixed determinants, and age, sex, BMI, waist and hip circumference, heamaglobin, serum creatinine, serum alanine transaminase, smoking, alcohol consumption, carbohydrate intake, fiber intake, iron intake, vitamin b1 and b6 intake, vitamin C intake as potential determinants. Determinants in the multivariate model were included based on a stepwise backward selection procedure with *P* \< 0.10 considered statistically significant. Continuous determinants were standardized into a Z-score. The set of significant predictors in the multivariate model constructed within the first wave was replicated as a multivariate model in the data of the second wave. Variables were considered as determinants of HbA~1c~ if there was a significant association in the multivariable model in both cohorts. Effect-modification was investigated by including interaction terms between sex and other independent variables in the linear regression models. Interaction terms were considered statistically significant with *P* \< 0.10. The explained variance of the models was estimated by the median R^2^ of the imputed datasets \[[@pone.0233769.ref029]\]. All analyses were performed using IBM SPSS Statistics version 22 for Windows (SPSS, Chicago, IL, USA).

Results {#sec011}
=======

[Table 1](#pone.0233769.t001){ref-type="table"} presents the population characteristics of the first (1989) and the second (2006) wave of the Hoorn Study. At the time of examination, participants from the first wave were on average 7.5 years older (61.4 ± 7.3) than those of the second wave (53.9 ± 6.7). Furthermore, the proportion of current smokers was substantially greater in the first (31.5%) than in the second wave (21.0%), whereas the median alcohol consumption in the second wave (8.2 g/day) was approximately two times higher than in the first wave (4.3 g/day). The Spearman correlations ([Table 1](#pone.0233769.t001){ref-type="table"}) of FPG with HbA~1c~ were stronger in both waves of the Hoorn Study (first: *r* = 0.32; second: *r* = 0.42) than the correlations of 2hPG with HbA~1c~ (first: *r* = 0.22; second: *r* = 0.31). Of all participants who were diagnosed with diabetes according to at least one of the screening tools (FPG ≥ 7.0 mmol/l or 2hPG ≥ 11.1 mmol/l or HbA~1c~ ≥ 6.5% (48 mmol/mol)), 23.8% (first) and 12.1% (second) were diagnosed with diabetes according to all three screening tools ([Fig 1](#pone.0233769.g001){ref-type="fig"}).

![Diagnosis of diabetes.\
The percentage of participants diagnosed with diabetes in the first wave *(n = 181 out of 2309)* and the second *wave (n = 108 out of 2612)*. Diabetes mellitus was diagnosed when at least one of the following criteria were met: FPG ≥ 7.0 mmol/l; 2hPG ≥ 11.1 mmol/l; HbA~1c~ ≥ 48 mmol/mol (6.5%).](pone.0233769.g001){#pone.0233769.g001}

10.1371/journal.pone.0233769.t001

###### Population characteristics and Spearman correlations of the participants of the Hoorn Study.

![](pone.0233769.t001){#pone.0233769.t001g}

                                                           First wave                                   Second wave
  -------------------------------------------------------- -------------------------------------------- --------------------------------------------
  *N*                                                      2309                                         2619
  Age (years)                                              61.4 ± 7.3                                   53.9 ± 6.7
  Female sex (%)                                           54.2                                         54.0
  BMI (kg/m^2^)                                            26.5 ± 3.5                                   26.1 ± 3.9
  Waist circumference (cm)                                 90.6 ± 10.7                                  89.4 ± 11.4
  Hip circumference (cm)                                   101.6 ± 6.7                                  100.3 ± 7.9
  Fasting plasma glucose (mmol/l)                          5.6 ± 1.0                                    5.5 ± 0.8
  2h post-load glucose (mmol/l)                            6.1 ± 2.8                                    5.7 ± 2.0
  HbA~1c~ (mmol/mol)                                       36.0 ± 7.7                                   36.0 ± 4.4
  HbA~1c~ (%)                                              5.4 ± 0.7                                    5.4 ± 0.4
  Haemoglobin (mmol/l)                                     9.0 ± 0.8                                    N/A
  Serum alanine transaminase (IU/l)                        11.0 (8.0--15.0)                             N/A
  Serum creatinine (μmol/l)                                90.1 ± 15.6                                  N/A
  Current smoker (%)                                       31.5                                         21.0
  Total energy intake (kcal/day)                           2067.6 ± 581.5                               2128.4 ± 665.0
  Alcohol consumption (g/day)                              4.3 (0.0--12.5)                              8.2 (2.1--19.6)
  Carbohydrate intake (g/day)                              213.9 ± 65.8                                 243.6 ± 80.5
  Fiber intake (g/day)                                     27.2 ± 7.9                                   N/A
  Iron intake (mg/day)                                     12.5 ± 3.1                                   11.0 ± 3.0
  Vitamin B1 intake (mg/day)                               1.1 ± 0.3                                    1.2 ± 0.4
  Vitamin B6 intake (mg/day)                               1.4 ± 0.4                                    1.7 ± 0.5
  Vitamin C intake (mg/day)                                95.3 (67.2--134.1)                           92.0 (67.1--119.7)
  FPG vs. HbA~1c~[^a^](#t001fn002){ref-type="table-fn"}    0.32[^b^](#t001fn003){ref-type="table-fn"}   0.42[^b^](#t001fn003){ref-type="table-fn"}
  2hPG vs. HbA~1c~[^a^](#t001fn002){ref-type="table-fn"}   0.22[^b^](#t001fn003){ref-type="table-fn"}   0.31[^b^](#t001fn003){ref-type="table-fn"}
  FPG vs. 2hPG[^a^](#t001fn002){ref-type="table-fn"}       0.42[^b^](#t001fn003){ref-type="table-fn"}   0.37[^b^](#t001fn003){ref-type="table-fn"}

N/A, not available; Values are means ± SD, median (25^th^--75^th^ percentile) or percentage.

^a^Spearman correlations.

^b^Statistically significant (*P* \< 0.05) correlation.

[Table 2](#pone.0233769.t002){ref-type="table"} shows the results of the multivariate linear regression models for both the first and the second wave (replication analysis). No interactions (*P* \> 0.10 for interaction terms) were found between sex and other independent variables in the multivariate model. In the first wave, independent of glucose, significant associations were found for age, sex, BMI, waist circumference, hip circumference, serum creatinine, smoking, alcohol consumption, carbohydrate intake, fiber intake and vitamin C intake in the multivariate model with HbA~1c~. Of these variables, age, sex, BMI, waist circumference, hip circumference, smoking, alcohol consumption and vitamin C intake were confirmed as statistically significant associations in the second wave. In the second wave, one SD increase in age (6.7 years) was associated with a 0.03% (95% CI, 0.03, 0.04) higher HbA~1c~ level. On average females had a 0.08% (0.07, 0.09) higher HbA~1c~ level than men. The quartiles of BMI and hip circumference showed a negative association with HbA~1c~, while waist circumference was positively associated. Smokers had a 0.10% (0.09, 0.11) higher HbA~1c~ level than non-smokers, whereas alcohol consumption was associated with a 0.07% (-0.07, -0.06) lower HbA~1c~ level per one SD increase (15.1 g/day). Quartiles of vitamin C intake were inversely associated with HbA~1c~. The multivariate association found in the first wave for carbohydrate intake was not confirmed in the second wave. Data on creatinine and fiber intake were not available in the second wave.

10.1371/journal.pone.0233769.t002

###### Multivariate linear regression models of associations of demographic, anthropometric, clinical and nutritional determinants with HbA1c independent of glucose in the Hoorn Study.

![](pone.0233769.t002){#pone.0233769.t002g}

                                                                                        First wave (*n* = 2309)                   Second wave (*n* = 2619)                            
  -------------------------------------------------------------------------------- ---- ------------------------- --------------- -------------------------- -------- --------------- ---------
  FPG (mmol/l) per SD = 1.0 in first wave / 0.8 in second wave                          0.353                     0.299;0.358     \<0.001                    0.272    0.266;0.278     \<0.001
  2hPG (mmol/l) per SD = 2.9 / 2.0                                                      0.109                     0.079;0.139     \<0.001                    0.060    0.054;0.065     \<0.001
  Age per SD = 7.3 / 6.7                                                                0.052                     0.031;0.073     \<0.001                    0.031    0.027;0.036     \<0.001
  Sex F/M (ref)                                                                         0.096                     0.036;0.155     0.002                      0.081    0.069;0.092     \<0.001
  BMI (kg/m^2^)                                                                    Q1   0                                                                    0                        
                                                                                   Q2   -0.119                    -0.182;-0.057   \<0.001                    -0.015   -0.029;-0.001   0.039
                                                                                   Q3   -0.094                    -0.165;-0.022   0.011                      -0.016   -0.033;0.001    0.068
                                                                                   Q4   -0.135                    -0.228;-0.043   0.004                      -0.022   -0.044;0.001    0.061
  Waist circumference (cm) per SD = 10.7 / 11.4                                         0.047                     0.012;0.081     0.009                      0.015    0.006;0.024     0.001
  Hip circumference (cm)                                                           Q1   0                                                                    0                        
                                                                                   Q2   -0.058                    -0.117;0.002    0.059                      -0.013   -0.027;0        0.057
                                                                                   Q3   -0.002                    -0.068;0.065    0.953                      -0.029   -0.045;-0.013   \<0.001
                                                                                   Q4   -0.025                    -0.105;0.055    0.537                      -0.015   -0.035;0.005    0.131
  Serum creatinine (μmol/l)                                                        Q1   0                                                                    N/A                      
                                                                                   Q2   0.023                     -0.033;0.080    0.417                      N/A                      
                                                                                   Q3   0.055                     -0.007;0.116    0.081                      N/A                      
                                                                                   Q4   0.092                     0.024;0.160     0.008                      N/A                      
  Current smoking Y/N (ref)                                                             0.236                     0.191;0.281     \<0.001                    0.101    0.090;0.112     \<0.001
  Alcohol consumption[^a^](#t002fn003){ref-type="table-fn"} per SD = 12.4 / 15.1        -0.086                    -0.108;-0.063   \<0.001                    -0.065   -0.070;-0.059   \<0.001
  Carbohydrate intake[^a^](#t002fn003){ref-type="table-fn"} per SD = 65.8 / 80.5        -0.028                    -0.050;-0.005   0.018                      0.000    -0.005;0.005    0.996
  Fiber intake[^a^](#t002fn003){ref-type="table-fn"} per SD = 7.9 / NA                  0.020                     -0.004;0.044    0.096                      N/A                      
  Vitamin C intake[^a^](#t002fn003){ref-type="table-fn"}                           Q1   0                                                                    0                        
                                                                                   Q2   -0.057                    -0.114;-0.001   0.048                      -0.032   -0.045;-0.020   \<0.001
                                                                                   Q3   -0.075                    -0.134;-0.016   0.013                      -0.040   -0.053;-0.027   \<0.001
                                                                                   Q4   -0.113                    -0.175;-0.051   \<0.001                    -0.038   -0.052;-0.025   \<0.001

N/A, not available; Q, Quartile (range); First wave; BMI, Q1 (\<24.1) Q2 (24.1;26.1) Q3 (26.2;28.3) Q4 (\>28.3); Hip circumference, Q1 (\<97.5) Q2 (97.5;101.9) Q3 (102.0;106.7) Q4 (\>106.7) Serum creatinine, Q1 (\<79.0) Q2 (79.0;88.0) Q3 (88.1;98.0) Q4 (\>98.0); Vitamin C, Q1 (\< -0.7) Q2 (-0.7;-0.2) Q3 (-0.1;0.6) Q4 (\>0.6). Second wave; BMI, Q1(\<23.4) Q2 (23.4;25.6) Q3(25.7;28.2) Q4 (\>28.2); Hip circumference, Q1 (\<95.4) Q2 (95.4;99.8) Q3 (99.9;105.2) Q4 (\>105.2); Vitamin C, Q1 (\< -0.7) Q2 (-0.7; -0.1) Q3 (0.0; 0.6) Q4 (\>0.6); Multivariate linear regression models regarding potential determinants and outcome HbA~1c~, in addition to fasting plasma glucose and 2h post-load glucose.

First wave complete model; R^2^ 46.7%. FPG + 2hPG; R^2^ 41.0%. (non-glycemic additional 5.7%) FPG; R^2^ 39.5%. 2hPG; R^2^ 29.7%. Phenotypic and lifestyle determinants; R^2^ 11.1%. Second wave complete model; R^2^ 56.9%. FPG + 2hPG; R^2^ 53.0%. (non-glycemic additional 3.9%) FPG; R^2^ 51.2%. 2hPG; R^2^ 27.9%. Phenotypic and lifestyle; R^2^ 10.3%.

^a^Corrected for total energy intake by the residual method.

FPG alone explained 39.5% (first) and 51.2% (second) of the total variance in HbA~1c~. FPG and 2hPG together explained 41.0% and 53.0% of variance in HbA~1c~. Phenotypic and lifestyle determinants in combination with both FPG and 2hPG explained an additional 5.7% in the first wave and 3.9% in the second wave. Models containing phenotypic and lifestyle determinants without glucose explained 11.1% and 10.3% of variance in HbA~1c~.

Discussion {#sec012}
==========

The current study investigated potential determinants of HbA~1c~, independent of FPG and 2hPG. In two independent cohorts, we found that higher age, female sex, larger waist circumference and smoking were associated with a higher HbA~1c~ level, whereas larger hip circumference, higher BMI, higher alcohol consumption and vitamin C intake were associated with a lower HbA~1c~ level. The key finding of this study was that glycemic variables explained the vast majority of the variation in HbA~1c~, while the contribution of phenotypic and lifestyle determinants was relatively small.

Our findings that age, sex, BMI, waist and hip circumference, smoking, alcohol consumption and vitamin C intake are associated with HbA~1c~ in two independent cohorts is consistent with available evidence. In line with previous studies \[[@pone.0233769.ref013], [@pone.0233769.ref030], [@pone.0233769.ref031]\], we observed that age and smoking are associated with HbA~1c~ independent of glucose. The current study reported a higher HbA~1c~ level in women than in men, after correction of glucose levels. Previous studies that did not account for glucose reported higher levels of HbA~1c~ in men, which is assumed to be the result of a longer erythrocyte lifespan in men \[[@pone.0233769.ref016], [@pone.0233769.ref032]\]. Similarly, we observed a higher HbA~1c~ level in men when we did not correct for glucose. In the present study we found independent and opposite associations of waist and hip circumference with HbA~1c~. Larger waist, and smaller hip circumference has previously been shown to be associated with risk for developing type 2 diabetes, independent of BMI \[[@pone.0233769.ref033], [@pone.0233769.ref034]\]. Our current findings showing associations between body composition and HbA~1c~, independent of glucose measures are novel. The same is true for alcohol consumption which has been associated with a lower HbA~1c~ level and improved insulin resistance in previous observational and intervention studies, but not particularly with HbA~1c~ independent of glucose \[[@pone.0233769.ref035]--[@pone.0233769.ref037]\]. The mechanism by which alcohol would improve insulin sensitivity is currently not resolved. Similarly, our finding that vitamin C intake was associated with a lower HbA~1c~ level has been reported in previous observational studies, but not independent of glucose \[[@pone.0233769.ref038], [@pone.0233769.ref039]\]. As suggested by Davie et al. \[[@pone.0233769.ref040]\], this relationship is possibly not mediated by glucose but caused by a competition between vitamin C and glucose to react with the protein amino group, thereby reducing glycation of haemoglobin.

In both the first (46.7%) and second wave (56.9%) model we found a substantially higher explained variance in HbA~1c~ as compared to a multivariate model created by Jansen et al. (26.2%), which contained some phenotypic, clinical, lifestyle and genetic determinants, in addition to FPG \[[@pone.0233769.ref013]\]. This difference is already apparent in a model with FPG alone, which explained 10.9% of the variance in HbA~1c~ in the study by Jansen et al., whereas it explained 39.5% (first) and 51.2% (second) in the current study. One reason for this difference may be the larger variation in HbA~1c~ in our study compared to Jansen et al. The standard deviation of HbA~1c~ was 0.7% and 0.4% in the Hoorn Study, while this was only 0.3% in the study by Jansen et al.

The present study and previous studies indicate that HbA~1c~ may reflect in part aging processes, body composition, smoking and dietary habits. These findings contribute to better understanding of the relatively poor correlations between glucose and HbA~1c~ observed in a previous investigation in the second wave \[[@pone.0233769.ref025]\] and other population-based studies \[[@pone.0233769.ref007]\]. In individuals with levels of HbA~1c~ that are higher or lower than expected based on glucose levels, the present data may provide clues for explaining such disagreement. Furthermore, presently identified determinants of HbA~1c~ might explain the stronger relationship with CVD observed in previous studies \[[@pone.0233769.ref004]--[@pone.0233769.ref006]\]. Future prospective studies are needed to better understand which factors explain or mediate the relationship between HbA1c and CVD.

The main strength of our study is the investigation of a combined set of potential determinants of HbA~1c~, in addition to both FPG and 2hPG, which provides a better reflection of diurnal glucose than FPG alone. Another strength of this study is the selection of potential determinants identified by previous studies, and the replication of the analyses in independent data, both limiting the probability of chance-findings. Our study also has some limitations. Firstly, several potential determinants of HbA~1c~, such as erythrocyte lifespan, vitamin B12 and E, genetic factors, rheumatoid arthritis and antiretrovirals could not be taken into account. Particularly erythrocyte lifespan could be of significant influence on HbA~1c~ levels because the glycation of haemoglobin partially depends on it \[[@pone.0233769.ref011]\]. Secondly, data on serum creatinine and fiber intake were not available in the second wave. Therefore, the model of the first wave could not be exactly replicated in the second wave.

In summary, the current study shows that, in addition to both FPG and 2hPG, age, sex, BMI, waist and hip circumference, smoking, alcohol consumption and vitamin C intake are associated with HbA~1c~ in the general population. Although the variation in HbA~1c~ explained by these factors is relatively low, it suggests that variation in HbA~1c~ levels apart from glucose may also be partially determined by phenotypic and lifestyle factors. These findings contribute to better understanding of the low correlation between glucose levels and HbA~1c~ in the general population.

We would like to thank WUR for dietary intake data linkage with NEVO and calculations.
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2\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.
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Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript is technically reasonable, the data is reliable, and appropriate and rigorous statistical analysis is performed, but the conclusions need to be further proved. The manuscript is presented in an intelligible fashion and written in standard English, but the author failed to provide important factors such as hemoglobin and serum alanine aminotransferase in the manuscript. Needs further research and reveals.

Reviewer \#2: General Comments

This is a very important and interesting study. The replication element of the study greatly increases its impact. It is important to determine the relation between the potential determinants of HbA1c and HbA1c itself.

Specific comments

Methods

A breakdown of Ethnicity of the participants would be very helpful -- sorry if I missed this

Results

Please can a Figure be included to display the results of the multivariate regression analysis as described in Table 2. This always aids data appreciation from a reader perspective.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Dr. Adrian Heald

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Click here for additional data file.
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24 Apr 2020

Reviewer \#1:

Summary:

This manuscript by Willem et al. entitled "Phenotypic and lifestyle determinants of HbA1c in the general population -- the Hoorn Studies" is aimed at understanding the relevance of phenotypic and lifestyle factors to HbA1c, in the general population. The data of both cohorts, independent of FPG and 2hPG, higher age, female sex, larger waist circumference, and smoking were associated with a higher HbA1c level. Larger hip circumference, higher BMI, higher alcohol consumption and vitamin C intake were associated with a lower HbA1c level. FPG and 2hPG together explained 41.0% (HS) and 53.0% (NHS) of the total variance in HbA1c. The authors fully describe the relationship between lifestyle, blood glucose levels and glycated hemoglobin in NHS and HS. There are several concerns to consider.

Major:

This study is simply a description and fails to give a reasonable explanation. The results of BMI related to increased hip circumference and low-grade glycated hemoglobin are interesting, but there is no explanation. In general, glycated hemoglobin is a non-independent diagnostic standard for diabetes. In this study, as a key point to explore, the actual or predictive role of glycated hemoglobin changes in the model population should be more revealed. At present, I cannot appreciate the value of the information provided by the research to clinical or public nutrition research. I hope researchers can further discuss and reveal the significance of the research.

Response: We thank the reviewer for careful reading of the paper and for addressing these important points. We will respond to these in a point-by-point answer below.

1．The trend of BMI results in HS from Q1 to Q4 is inconsistent. Can this result be adopted?

Response: the trend over quartiles BMI in the HS cohort is indeed slightly inconsistent. This inverse association of BMI with HbA1c is partly due to the model being multivariate and including hip and waist circumference as well as fasting and post-load glucose. This will make closely related estimates somewhat unstable. Therefore, we avoided to speculate on the importance of this slightly inconsistent association over BMI quartiles.

2\. Hemoglobin and serum alanine aminotransferase are important factors affecting glycated hemoglobin, which are not shown in the analysis results, can they be explained?

Response: Hemoglobin and serum alanine aminotransferase were indeed considered potential determinants of HbA1c in addition to glucose measures. These factors were added to the multivariable model of the HS cohort in a stepwise procedure. However both did not appear statistical significant determinants at level P\< 0.10 and were therefore not presented in Table 2. Serum alanine transferase indeed was an important determinant, that was excluded in the final model with a p-value of 0.25, while hemoglobin was already excluded earlier in the analysis.

3\. Can I know the results about the investigator\'s medication history?

Response: the medication history for blood glucose lowering medication was considered in the study. All study participants with diabetes and thus also those who were using blood glucose lowering medication were excluded from the analysis. This is indicated more clearly now on page 5 line 98 and 106.

4\. The author\'s study showed a negative correlation between the amount of alcohol consumed and the content of glycated hemoglobin, which means that increased drinking in healthy people is beneficial to prevent blood sugar rising. Can I understand it this way?

Response: The study shows an inverse association between alcohol intake and glycated hemoglobin in two independent cohorts, but causality cannot be concluded from observational studies. The finding is not unique. Several observational studies have reported an inverse association between alcohol consumption and HbA1c or insulin resistance (refs 35-37). Moreover, moderate alcohol consumption is shown to reduce HbA1c and insulin resistance in multiple intervention studies as summarized in a meta-analysis (Schrieks IC, diabetes care). Therefore, this finding is consistent with other studies, but the mechanism is currently not resolved. We have now indicated this briefly in the discussion section of the paper as follows; 'The same is true for alcohol consumption which has been associated with a lower HbA1c level and improved insulin resistance in previous observational and intervention studies, but not particularly with HbA1c independent of glucose \[35-37\]. The mechanism by which alcohol would improve insulin sensitivity is currently not resolved.'

5\. The author further explains the significance of the findings for metabolic or cardiovascular disease will be appreciated. (The significance of the study is unclear because the glycated hemoglobin in the study fluctuates within the normal range)

Response: The main relevance of the paper is related to the use of HbA1c levels for the diagnosis of diabetes. Since disagreement in diagnosis by HbA1c and glucose is observed in other studies, it is important to understand the contributing factors to HbA1c beyond glucose. Increased HbA1c levels are associated with future CVD incidence. This association is also apparent among individuals with levels of HbA1c in the normal range (Khaw KT (2004) Ann Intern Med 141: 413-420 and Di Angelantonio E (2014) Jama-J Am Med Assoc 311: 1225-1233). The author is right that this point was not particularly articulated in the paper. Therefore we added this sentence in the introduction section:

"HbA1c has also been shown to be a more accurate marker than measures of glucose for future risk of diabetes complications, such as micro vascular complications and cardiovascular disease (CVD), in individuals with type 2 diabetes \[4\]. In addition, higher HbA1c is associated with higher risk for CVD and total mortality \[5, 6\]. This increased CVD and mortality risk with higher HbA1c is already seen at levels in the normal range \[5, 6\].

6\. The conclusion that women\'s hemoglobin is higher than men\'s is also worthy of our attention. It would be greatly appreciated if the author could further analyze the pre- and post-menopausal women. (Because previous studies have shown that estrogen treatment can increase glycated hemoglobin levels)

Response: This is an interesting suggestion. The current findings were in contrast with other studies where a higher HbA1c was found in men \[REF 15\]. And a study were HbA1c was lower in women before menopause as compared to men \[REF 31\]. However, in previous studies, no adjustment was made for glucose levels. As explained in the discussion section line 263, similar to these previous studies, we also observed a higher HbA1c level in men when we did not correct for glucose. In the current study, the higher HbA1c levels in women were consistently found in both cohorts, in which age, and hence the proportion of postmenopausal women, was different. This suggests that the observed higher HbA1c levels, at similar glucose concentration, were not specific for postmenopausal women or women using estrogen treatment. In addition, in both cohorts only a small proportion of women was premenopausal with 5.5% in the HS and approximately 15% in NHS. We considered that the subsample of premenopausal women was too small to conduct a stratified analysis.

Reviewer \#2: General Comments

This is a very important and interesting study. The replication element of the study greatly increases its impact. It is important to determine the relation between the potential determinants of HbA1c and HbA1c itself.

Specific comments

Methods

A breakdown of Ethnicity of the participants would be very helpful -- sorry if I missed this

Response: In the HS cohort, only Caucasians were part of the cohort. In the NHS only 4.5% of individuals were non-Caucasian. We considered that the subsample of non-Caucasians was too small for a subanalysis.

Results

Please can a Figure be included to display the results of the multivariate regression analysis as described in Table 2. This always aids data appreciation from a reader perspective.

Response: thank you for the suggestion. We are not sure how this would add to the current information since a Figure does not provide specific numbers. Therefore, we prefer the data being presented in a Table.
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Dear MSc Wisgerhof 

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Xianwu Cheng, M.D., Ph.D., FAHA

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All original concerns have been addressed by the authors.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have shown a lot of effort to improve the manuscript and this should be well appreciated. I found the authors have addressed all my comments carefully by adding more materials in the text. As a result, I now recommend the current form can be accepted for publication without further modification.

Reviewer \#2: Please can you accept this excellent paper

I already emailed your office twice to say \"ACCEPT\"

Kind regards

Dr. Adrian Heald

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Dr. Adrian Heald
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Phenotypic and lifestyle determinants of HbA1c in the general population -- the Hoorn Study

Dear Dr. Wisgerhof:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Associate Prof. Xianwu Cheng

Academic Editor

PLOS ONE
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